Cannabinoids and cancer pain: A new hope or a false dawn?

Eur J Intern Med. 2018 Mar:49:30-36. doi: 10.1016/j.ejim.2018.01.020.

Abstract

The endocannabinoid system is involved in many areas of physiological function and homeostasis. Cannabinoid receptors are expressed in the peripheral and central nervous system and on immune cells, all areas ideally suited to modulation of pain processing. There are a wealth of preclinical data in a number of acute, chronic, neuropathic and cancer pain models that have demonstrated a potent analgesic potential for cannabinoids, especially in patients with cancer. However, although there are some positive results in pain of cancer patients, the clinical evidence for cannabinoids as analgesics has not been convincing and their use can only be weakly recommended. The efficacy of cannabinoids seems to have been 'lost in translation' which may in part be related to using extracts of herbal cannabis rather than targeted selective full agonists at the cannabinoid CB1 and CB2 receptors.

Keywords: Analgesia; CB1 receptor; CB2 receptor; Endocannabinoids; Fatty acid amide hydrolase; Malignancy.

Publication types

  • Review

MeSH terms

  • Animals
  • Cancer Pain / drug therapy*
  • Cannabinoid Receptor Agonists / metabolism*
  • Cannabinoids / therapeutic use*
  • Humans
  • Mice
  • Peripheral Nervous System Diseases / drug therapy
  • Peripheral Nervous System Diseases / etiology

Substances

  • Cannabinoid Receptor Agonists
  • Cannabinoids